Skip to Main Content

Author Details

Chengjin Ye
Texas Biomedical Research Institute
2013
67
18
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38064030Plasmid-Based Lassa Virus Reverse Genetics.Methods Mol Biol2024
38064031Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2.Methods Mol Biol2024
34159337Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects.bioRxiv2023
38014074SARS-CoV-2 nsp15 endoribonuclease antagonizes dsRNA-induced antiviral signaling.bioRxiv2023
37796985A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.Proc Natl Acad Sci U S A2023
37581931Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects.J Clin Invest2023
37738983Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.Cell Host Microbe2023
37738970SARS-CoV-2 variants evolve convergent strategies to remodel the host response.Cell2023
37738347Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5.Sci Adv2023
37191507Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission.Microbiol Spectr2023
37288969A new tractable method for generating human alveolar macrophage-like cells <i>in vitro</i> to study lung inflammatory processes and diseases.mBio2023
36989354Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.Sci Adv2023
37345956SARS-CoV-2 hijacks p38β/MAPK11 to promote virus replication.mBio2023
37243110Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.Vaccines (Basel)2023
37163142Mitigation of SARS-CoV-2 by Using Transition Metal Nanozeolites and Quaternary Ammonium Compounds as Antiviral Agents in Suspensions and Soft Fabric Materials.Int J Nanomedicine2023
37066199A new tractable method for generating Human Alveolar Macrophage Like cells in vitro to study lung inflammatory processes and diseases.bioRxiv2023
36580912SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming.Cell2023
36194133SARS-CoV-2 3CL<sup>pro</sup> mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.Sci Transl Med2023
35080423Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice.J Virol2022
35738348Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.Antiviral Res2022
35821476Bioluminescent and Fluorescent Reporter-Expressing Recombinant SARS-CoV-2.Methods Mol Biol2022
35821475Generation of Bi-Reporter-Expressing Tri-Segmented Arenavirus.Methods Mol Biol2022
35862475Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.PLoS Pathog2022
36342302Use of a Bacterial Artificial Chromosome to Generate Recombinant SARS-CoV-2 Expressing Robust Levels of Reporter Genes.Microbiol Spectr2022
36146823Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics.Viruses2022
35994646SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.Proc Natl Acad Sci U S A2022
35895717A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.Proc Natl Acad Sci U S A2022
35890050GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2.Pathogens2022
35982678Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.bioRxiv2022
35980204Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus.Microbiol Spectr2022
35291292Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.bioRxiv2022
35313573Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal challenge and viral transmission.bioRxiv2022
35245585Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.J Infect2022
35036857SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening.ACS Pharmacol Transl Sci2022
33068703Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.J Virol Methods2021
33649747Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.Cell Rep Med2021
33513380Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.J Virol Methods2021
33532796The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.medRxiv2021
33688034A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.Proc Natl Acad Sci U S A2021
34495697A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>.J Virol2021
34379509A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.J Virol2021
34806704Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2.J Vis Exp2021
34741049Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.Nat Commun2021
34561300Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses.Proc Natl Acad Sci U S A2021
34268508A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening.bioRxiv2021
33972945SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern induce lethal disease in K18-hACE2 transgenic mice despite convalescent plasma therapy.bioRxiv2021
33431557Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes.J Virol2021
32209677A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.mBio2020
32024281A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs.Viruses2020
32098811A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.mBio2020
  • 1 - 50 of 67

Recommended Authors

Institut Pasteur, Center for the Viral Populations and Pathogenesis
Career Start Year 2017
Number of shared co-authors 23
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 2017
Number of shared co-authors 23
Gladstone Institutes
Career Start Year 2016
Number of shared co-authors 22
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Career Start Year 2015
Number of shared co-authors 26
University of North Carolina at Chapel Hill
Career Start Year 2014
Number of shared co-authors 2
University of Maryland School of Medicine
Career Start Year 2014
Number of shared co-authors 21
Duke University School of Medicine
Career Start Year 2012
Number of shared co-authors 4
University of Texas Medical Branch
Career Start Year 2012
Number of shared co-authors 1
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 10
Stanford University School of Medicine
Career Start Year 2010
Number of shared co-authors 6
University of Texas Medical Branch
Career Start Year 2010
Number of shared co-authors 5
Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 6
University of Texas Medical Branch
Career Start Year 2009
Number of shared co-authors 1
University of Texas Medical Branch
Career Start Year 2008
Number of shared co-authors 0
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 3
University of Texas Medical Branch
Career Start Year 2008
Number of shared co-authors 5
National Center for Toxicological Research
Career Start Year 2005
Number of shared co-authors 0
University of North Carolina
Career Start Year 2004
Number of shared co-authors 0
National Institute of Allergy and Infectious Disease, National Institute of Health
Career Start Year 2003
Number of shared co-authors 0
University of North Carolina at Chapel Hill
Career Start Year 2003
Number of shared co-authors 3
Centers for Disease Control and Prevention (CDC)
Career Start Year 2003
Number of shared co-authors 2
University of Iowa
Career Start Year 2002
Number of shared co-authors 10
The University of North Carolina at Chapel Hill
Career Start Year 1998
Number of shared co-authors 0
University of Texas Medical Branch
Career Start Year 1996
Number of shared co-authors 6
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 1993
Number of shared co-authors 25
University of North Carolina at Chapel Hill
Career Start Year 1993
Number of shared co-authors 1
University College London
Career Start Year 1992
Number of shared co-authors 25
The University of Texas Medical Branch
Career Start Year 1991
Number of shared co-authors 0
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 3
University of North Carolina
Career Start Year 1981
Number of shared co-authors 8

Collaborators

Texas Biomedical Research Institute
Co-authored papers 51
University of Washington Medical Center
Co-authored papers 5
Stanford University School of Medicine
Co-authored papers 3
University of Texas Health San Antonio
Co-authored papers 3
Co-authored papers 3
Texas Biomedical Research Institute
Co-authored papers 3
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Texas Biomedical Research Institute
Co-authored papers 2
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Co-authored papers 2
J. David Gladstone Institutes
Co-authored papers 2
J. David Gladstone Institutes
Co-authored papers 2
University of California, San Francisco
Co-authored papers 2
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
J. David Gladstone Institutes
Co-authored papers 2
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
J. David Gladstone Institutes
Co-authored papers 2
Icahn School of Medicine at Mount Sinai New York
Co-authored papers 2
University of South Florida
Co-authored papers 2
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
University of California
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Stanford University School of Medicine
Co-authored papers 1
University College London, The Francis Crick Institute
Co-authored papers 1
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 1
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
MRC-University of Glasgow Centre for Virus Research, University of Glasgow
Co-authored papers 1
Co-authored papers 1